In the past week, BCYC stock has gone down by -27.42%, with a monthly decline of -30.52% and a quarterly plunge of -37.85%. The volatility ratio for the week is 14.69%, and the volatility levels for the last 30 days are 7.54% for Bicycle Therapeutics Plc ADR The simple moving average for the past 20 days is -22.00% for BCYC’s stock, with a -33.97% simple moving average for the past 200 days.
Is It Worth Investing in Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Right Now?
The 36-month beta value for BCYC is also noteworthy at 0.86. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCYC is 65.57M, and at present, short sellers hold a 5.17% of that float. The average trading volume of BCYC on December 18, 2024 was 558.79K shares.
BCYC) stock’s latest price update
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) has experienced a rise in its stock price by 0.13 compared to its previous closing price of 15.12. However, the company has seen a fall of -27.42% in its stock price over the last five trading days. businesswire.com reported 2024-12-12 that CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with Stephens repeating the rating for BCYC by listing it as a “Equal-Weight.” The predicted price for BCYC in the upcoming period, according to Stephens is $25 based on the research report published on November 08, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $35. The rating they have provided for BCYC stocks is “Outperform” according to the report published on September 06th, 2024.
B. Riley Securities gave a rating of “Neutral” to BCYC, setting the target price at $28 in the report published on August 07th of the current year.
BCYC Trading at -32.75% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.19% of loss for the given period.
Volatility was left at 7.54%, however, over the last 30 days, the volatility rate increased by 14.69%, as shares sank -26.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.30% lower at present.
During the last 5 trading sessions, BCYC fell by -27.42%, which changed the moving average for the period of 200-days by -38.05% in comparison to the 20-day moving average, which settled at $19.41. In addition, Bicycle Therapeutics Plc ADR saw -16.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from BAKER BROS. ADVISORS LP, who purchase 985,397 shares at the price of $13.76 back on Dec 13 ’24. After this action, BAKER BROS. ADVISORS LP now owns 9,537,643 shares of Bicycle Therapeutics Plc ADR, valued at $13,559,485 using the latest closing price.
BAKER BROS. ADVISORS LP, the Director of Bicycle Therapeutics Plc ADR, purchase 500,000 shares at $15.34 during a trade that took place back on Dec 16 ’24, which means that BAKER BROS. ADVISORS LP is holding 9,995,274 shares at $7,670,900 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -5.95 for the present operating margin
- 0.81 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -4.51. The total capital return value is set at -0.23. Equity return is now at value -26.82, with -20.45 for asset returns.
Currently, EBITDA for the company is -183.4 million with net debt to EBITDA at 4.85. When we switch over and look at the enterprise to sales, we see a ratio of 4.48. The receivables turnover for the company is 0.64for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.13.
Conclusion
In summary, Bicycle Therapeutics Plc ADR (BCYC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
